article thumbnail

Is that really ADHD? Why flawed trials may be misleading millions

Science Daily: Pharmacology News

Researchers reviewing nearly 300 top-tier ADHD drug trials found that half skipped the rigorous, expert-led evaluations needed to rule out other conditions like depression or schizophrenia.

article thumbnail

Tofersen

New Drug Approvals

Tofersen , sold under the brand name Qalsody , is a medication used for the treatment of amyotrophic lateral sclerosis (ALS). [3] 3] Tofersen is an antisense oligonucleotide that targets the production of superoxide dismutase 1 , an enzyme whose mutant form is commonly associated with amyotrophic lateral sclerosis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inavolisib

New Drug Approvals

2] [3] It is an inhibitor and degrader of mutant phosphatidylinositol 3-kinase (PI3K) alpha. [4] 4] The PI3K-mediated signalling pathway has shown to play an important role in the development of tumours as dysregulation is commonly associated with tumour growth and resistance to antineoplastic agents and radiotherapy. [5]

FDA
article thumbnail

Vamorolone

New Drug Approvals

Drug Trials Snapshots: Agamree” U.S. Food and Drug Administration (FDA). “Drug Approval Package: Agamree” U.S. . “Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy” Life Sci Alliance. 2 (1): e201800186. doi : 10.26508/lsa.201800186.

FDA
article thumbnail

Elacestrant 

New Drug Approvals

1] [4] It is taken by mouth. [1] 1] [4] Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors , which are the biological targets of endogenous estrogens like estradiol. [1] 2] Elacestrant was approved for medical use in the United States in January 2023, [1] [2] [5] [6] and in the European Union in September 2023. [3]

FDA
article thumbnail

Pirtobrutinib

New Drug Approvals

Jump up to: a b c “Drug Trials Snapshots: Jaypirca” U.S. Food and Drug Administration (FDA). 1] [2] [4] It inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton’s tyrosine kinase (BTK). [5] 5] It is taken by mouth. [1] 2] PATENTS Guisot, N. 12 (5): 80. PMC 9123190.

article thumbnail

Zilucoplan

New Drug Approvals

6] [9] [10] It is a complement inhibitor that is injected subcutaneously (under the skin). [6] 6] Zilucoplan is a cyclic peptide that binds to the protein complement component 5 (C5) and inhibits its cleavage into C5a and C5b. [11] 1] Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide with formula C172H278N24O55.

FDA